164 related articles for article (PubMed ID: 9787317)
1. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia.
Dördelmann M; Reiter A; Zimmermann M; Fengler R; Henze G; Riehm H; Schrappe M
J Pediatr Hematol Oncol; 1998; 20(5):444-50. PubMed ID: 9787317
[TBL] [Abstract][Full Text] [Related]
2. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
4. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
[TBL] [Abstract][Full Text] [Related]
5. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
Moe PJ; Holen A; Nygaard R; Glomstein A; Madsen B; Hellebostad M; Stokland T; Wefring KW; Steen-Johnsen J; Nielsen B; Hapnes C; Børsting S
Pediatr Hematol Oncol; 2003; 20(3):187-200. PubMed ID: 12637215
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
8. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
9. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
[TBL] [Abstract][Full Text] [Related]
10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
11. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
Henze G; Fengler R; Hartmann R; Kornhuber B; Janka-Schaub G; Niethammer D; Riehm H
Blood; 1991 Sep; 78(5):1166-72. PubMed ID: 1878583
[TBL] [Abstract][Full Text] [Related]
12. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse.
Brecher ML; Weinberg V; Boyett JM; Sinks LF; Jones B; Glicksman A; Holland JF; Freeman AI
Cancer; 1986 Sep; 58(5):1024-8. PubMed ID: 3524797
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia.
Schrappe M; Reiter A; Riehm H
J Neurooncol; 1998; 38(2-3):159-65. PubMed ID: 9696367
[TBL] [Abstract][Full Text] [Related]
14. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
[TBL] [Abstract][Full Text] [Related]
15. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
[TBL] [Abstract][Full Text] [Related]
17. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
Tsurusawa M; Katano N; Yamamoto Y; Hirota T; Koizumi S; Watanabe A; Takeda T; Hatae Y; Yatabe M; Mimaya J; Gushiken T; Nishi K; Anami K; Kikuta A; Kanegane H; Asami K; Nishikawa K; Sekine I; Kawano Y; Iwai A; Furuyama T; Ijichi O; Miyake M; Mugishima H; Fujimoto T
Med Pediatr Oncol; 1999 Apr; 32(4):259-6. PubMed ID: 10102019
[TBL] [Abstract][Full Text] [Related]
18. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]